Ann: SECuRE trial update, page-107

Yep. But the earlier poster had discussed how there was a high false positive rate against the standard of care. The issue with the cobra trial is that it wasn't ethically feasible to biopsy every single lesion. They had only biopsied 9 patients against a cohort of 42. So the initial cobra trial still had to call a number of false positives which was most likely true positives because the standard of care was so poor. This showed that they probably didn't expect the stark difference vs standard of care(how poorly SoC performed), so they didn't expect to need to biopsy that many.

in their half yearly report they also expanded on their 78% accuracy of lesions highlighting, as 2 patients that were biopsied negative were in the prostate bed. They've stated that prostate bed lesions have a high false negative rate. If you look up information regarding this, it does seem to be true. Also we could see that a lymph node that was biopsied negative was positive on resection.

This is all irrelevant as the reference is the standard of truth ie histopathology. How they'll be able to confirm their accuracy is still to be determined. I'm not sure they can biopsy every positive lesion.